Revvity, Inc.

Revvity, Inc. is a comprehensive life science solutions provider serving academia, pharmaceutical, biotech, clinical laboratories, contract research organizations, and healthcare professionals globally. The company operates across the drug discovery-to-diagnostics continuum, delivering integrated workflows in translational multi-omics, biomarker identification, imaging, screening, detection, diagnosis, and informatics. Product portfolio includes high-content screening instruments (Opera Phenix, EnVision plate readers), optical imaging systems (IVIS), cell analysis instruments (Cellometer), sample preparation equipment (Omni Bead Ruptor Elite homogenizers), and laboratory automation (Fontus workstations, LabChip systems). Reagent brands encompass BioLegend antibodies and flow cytometry reagents, AlphaLISA and SureFire immunoassays, HTRF TR-FRET assays, Dharmacon RNAi and CRISPR tools, and custom oligonucleotide synthesis. Representative diagnostic and clinical service offerings include newborn screening (33M+ annual screens), immunodiagnostics via EUROIMMUN solutions (85M+ blood samples analyzed), infectious disease serology, TB testing (T-SPOT.TB, 20M+ tested since 2002), reproductive health solutions (maternal/prenatal testing, cell-free DNA analysis, preeclampsia management), and clinical genomics services (300M+ tests performed). Licensing portfolio covers gene expression, editing, and viral vector technologies including LentiBOOST and Pin-point base editing platforms. Revvity serves 94% of top 50 global pharma companies, maintains ~11,000 employees worldwide, and operates on-site manufacturing, viral vector engineering, preclinical oncology services, and clinical testing. Regulatory presence includes FDA and CE approvals across diagnostics and instruments. The company integrates acquisition-driven growth with organic R&D, supporting discovery through clinical deployment across life science workflows.